Strategic partnerships Leverage Hemerion’s university and hospital collaborations with Université de Lille, Inserm, and University Hospital of Lille to propose joint development programs, clinical trial co-funding opportunities, and translational research collaborations that can accelerate regulatory milestones and patient access.

US market entry Capitalize on recent U.S. strategy hires and ongoing sponsored clinical trial at UPMC to position as a preferred partner for U.S. pharma and biotech seeking glioblastoma or brain cancer attention, offering access to clinical sites, regulatory expertise, and potential deal flow.

Clinical pipeline Highlight the Pentalafen and Heliance combination as a differentiated front-line glioblastoma approach to align with investors and CROs seeking innovative, clinically advancing therapies, and explore partnerships for global trials and regulatory submissions.

Fundraising readiness Leverage Series A traction and seed funding history to engage strategic investors, CMOs, and life science funds for co-development, manufacturing scale-up, and commercialization planning, emphasizing near-term milestones and patient impact.

Thought leadership Utilize recent conference presence and the New Best Innovation Prize recognition to generate speaking engagements, sponsored sessions, and advisory opportunities that raise brand credibility and attract potential collaborators and opportunistic buyers.